Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab.
Teva announces FDA acceptance of sNDA for a higher concentration dose of COPAXONE® given three times a week
[Nicolau syndrome after administration of glatiramer acetate].
A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year.
A promising therapeutic approach for treatment of posterior uveitis: recombinant T cell receptor ligand protects Lewis rats from acute and recurrent experimental autoimmune uveitis.
Rituximab Use in Pediatric Central Demyelinating Disease.
Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS.
Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE.
First patient treated in Mapi Pharma's Phase IIa clinical trial of GA Depot for relapsing remitting multiple sclerosis (RRMS)
Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies.
Assessment of statistical significance and clinical relevance.
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci.
UPDATE 1-Teva Pharmaceutical banks on thrice-weekly Copaxone
New data analyses show significant clinical and MRI improvements with PLEGRIDY™ (peginterferon beta-1a)
Neuroprotective effect of masitinib in rats with postischemic stroke.
Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series.
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.
[The Sjögren's syndrome and multiple sclerosis: similarity and differences.]
Motor skill learning requires active central myelination.
Disrupted balance of T cells under natalizumab treatment in multiple sclerosis.
Benefit of Endermology on Indurations and Panniculitis/Lipoatrophy During Relapsing-Remitting Multiple Sclerosis Long-Term Treatment with Glatiramer Acetate.
Extoxnet (extension toxicology network), 4-aminopyridine
Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota.
Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multipl
Copolymer 1 inhibits manifestations of graft rejection.

Pages